daclatasvir (Daklinza®)

Reference No. 1464

Publication date:

20/05/2015

Appraisal information

daclatasvir (Daklinza®) 30 mg film-coated tablet
daclatasvir (Daklinza®) 60 mg film-coated tablet

Company:	Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category:	Infections
NMG meeting date:	25/02/2015
AWMSG meeting date:	25/03/2015

Submission Type:	Full Submission
Status:	Superseded
Advice No:	0615
Ratification by Welsh Government:	15/05/2015

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA364) NICE GUIDANCE ISSUED NOVEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Daclatasvir (Daklinza®) in combination with other medicinal products is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adults. Use should be restricted to patients with significant fibrosis (METAVIR score ≥ F3) or compensated cirrhosis. Daclatasvir (Daklinza®) in combination with other medicinal products is not recommended for use within NHS Wales outside of this subpopulation.

Final Appraisal Recommendation (FAR)

Download

daclatasvir (Daklinza) 1464 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

daclatasvir (Daklinza) 1464 ASAR

Clinical Expert (CE) Summary

Download

daclatasvir (Daklinza) 1464 CE Summary